AlgiPharma AS: Clinical Trials

6 trials sponsored by AlgiPharma AS, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 terminated, 1 withdrawn. 6 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 26Completed 4, Terminated 1, Withdrawn 1
Phase 11Completed 1
Phase 31Withdrawn 1

Follow AlgiPharma AS: new trials by email

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis
OligoG Dry powder for inhalation - Cystic Fibrosis
Phase 2 / Phase 3WithdrawnAlgiPharma AS2021-09-012022-06-30
A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients with Cystic Fibrosis
OligoG DPI - Cystic Fibrosis
Phase 2TerminatedAlgiPharma AS152019-05-162024-10-28
A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection
Alginate oligosaccharide, Placebo - Cystic Fibrosis, Burkholderia Infection
Phase 2CompletedAlgiPharma AS152015-02-012018-04-19
A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis
alginate oligosaccharide - Cystic Fibrosis
Phase 2CompletedAlgiPharma AS652014-10-012018-04-19
A Study to Investigate Lung Deposition of Radiolabelled OligoG
Radiolabelled OligoG CF-5/20 DPI, Radiolabelled OligoG CF-5/20 6% Solution - Cystic Fibrosis
Phase 2CompletedBDD Pharma Ltd102014-04-012015-02-09
A Cross-over Study of OligoG in Subjects With Cystic Fibrosis. Fibrosis
OligoG CF-5/20, Saline - Cystic Fibrosis
Phase 1 / Phase 2CompletedAlgiPharma AS262011-05-012015-01-14

Conditions studied

Cystic Fibrosis (6)  ·  Burkholderia Infections (1)

Interventions

oligoG CF-5-20 (3)  ·  Inhalation (2)  ·  Sodium Chloride (1)  ·  Solutions (1)

Countries

Germany (3)  ·  United Kingdom (3)  ·  Australia (1)  ·  Denmark (1)  ·  Ireland (1)  ·  Norway (1)  ·  Sweden (1)

Top investigators

Howard NE Stevens, PhD (1)  ·  Martin Walshaw, MD (1)  ·  Peter Wark (1)  ·  Rainald Fischer, MD, PD (1)  ·  Silke van Koningsbruggen-Rietschel, MD, PhD (1)  ·  Tacjana Pressler, PhD MD (1)

Results publications

PMID 32671834, PMID 35086790

NIH funding

2018 (1)